Category Archives: Pharmaceuticals industry

Million Pfizer jabs face being dumped after Israel-UK swap deal fails

Posted on by

Israel says technical issues have scuppered deal to give UK Covid vaccines expiring on 30 July

More than a million Pfizer/BioNTech vaccine doses held in Israel that are due to expire at the end of July may be thrown away after attempts to broker a swap deal with the UK failed.

Israel had reportedly offered the jabs to Britain in return for a similar number of vaccines that the UK is due to receive from Pfizer in September. Health authorities are racing to vaccinate as many of its adult population as possible before Covid restrictions are lifted in England later this month.

Continue reading...

‘Johnson & Johnson helped fuel this fire’ – now it’s out of the opioids business

Posted on by

Whether the pharmaceutical giant jumped or was pushed, its New York deal is a significant sign of the way the wind is blowing

Johnson & Johnson said it had already jumped. New York’s attorney general suggested the pharmaceutical giant was pushed.

Either way, the American drug maker is the first to formally agree to get out of the multibillion-dollar business of selling the powerful narcotic painkillers that drove the US opioid epidemic.

Continue reading...

The Oxford vaccine: the trials and tribulations of a world-saving jab

Posted on by

Amid bemusement from scientists at the deluge of often undeserved criticism, the Guardian pieces together the story behind the vaccine’s successes and failures

In January 2020, when most of the world slept soundly in ignorance of the pandemic coming its way, a group of scientists at Oxford University got to work on a vaccine to save the planet. They wanted it to be highly effective, cheap, and easy to use in even the poorest countries.

Prof Sarah Gilbert, Prof Andrew Pollard and others pulled it off. With speed crucial, they designed it and launched into trials before bringing in a business partner. The giant Anglo-Swedish pharmaceutical company AstraZeneca would manufacture it, license it around the world – and not make a profit until the pandemic was over.

Continue reading...

Covid jabs for billions of humans will earn their makers billions of dollars

Posted on by

We look at the drug firms – led by Pfizer and Moderna – that are set to profit most in an unprecedented global vaccination drive

Drugmakers led by US firms Pfizer and Moderna stand to make tens of billions of dollars from their Covid-19 vaccines this year and next, given G7 governments’ pledge to vaccinate the entire world by the end of 2022, but sales are likely to drop sharply thereafter, according to analysts.

Acclaimed for allowing a return to more normal life, Covid vaccines will also substantially benefit some pharmaceutical companies. The global market for the vaccines is worth $70bn (£50bn) this year, says Karen Andersen of Morningstar.

Continue reading...

EU fails in court action to secure urgent 120m doses of Oxford Covid vaccine

Posted on by

But Brussels court says AstraZeneca should have used UK plants in the past to fulfil EU deliveries

The EU has failed in a legal attempt to secure an urgent 120m vaccine doses from AstraZeneca by the end of this month, while securing a judgment that sites in Oxford and Staffordshire should have been used in the past to make good on deliveries.

The court of first instance in Brussels ordered the Anglo-Swedish company to deliver just 10m more than it has already provided by the end of September, and make “best efforts”, including potentially the use of UK facilities, to provide the further 220m jabs to which it is contractually committed.

Continue reading...

Drop Covid vaccine patent rules to save lives in poorest countries, Britain and Germany told

Posted on by

G7 summit hears move would slash the cost of jabs and accelerate rollout of programmes across the developing world

Britain and Germany were under intense pressure on Saturday to drop their resistance to proposals that would slash the cost of Covid-19 vaccines, following accusations that an agreement at the G7 summit to fund a billon doses will give the world’s poorest countries “crumbs from the table”.

Aid agencies said rules that protect drug patents from being illegally copied must be waived during the pandemic to accelerate the rollout of vaccines and save lives across the developing world.

Continue reading...

Thailand starts Covid vaccine drive using jabs made by king’s firm

Posted on by

Country aims to vaccinate 70% of people this year but experts express doubts amid supply concerns

Thailand has started its Covid vaccination campaign amid concerns over the supply of doses, which are mainly being produced locally by a royal-owned company that has no prior experience of making vaccines.

Thailand aims to vaccinate 70% of the population before the end of the year, and is relying primarily on AstraZeneca doses produced by Siam Bioscience, a company owned by King Maha Vajiralongkorn. The company is also due to supply vaccines to eight other countries in the region.

Continue reading...

MPs tell Johnson: you have a duty to help vaccinate the world

Posted on by

Exclusive: group urges prime minister to tackle ‘desperate shortage’ in developing nations

Boris Johnson has a “moral duty” to immediately start matching each vaccine administered at home with a donated dose to poorer countries across the world, a cross-party group of MPs and peers has said.

Several Tory backbenchers joined the call, which puts further pressure on the prime minister to boost supplies given to developing nations facing a “desperate shortage” of jabs.

Continue reading...

German scientists say they can help improve Covid vaccines to prevent blood clots

Posted on by

AstraZeneca and Johnson & Johnson jabs have caused rare blood clots but scientists say they can be redesigned to avoid problem

A team of German scientists believe that they have worked out why some people given the AstraZeneca and Johnson & Johnson vaccines against Covid-19 develop blood clots – and claim they can tell the manufacturers how to improve the vaccine to avoid it.

The key is in the adenovirus – the common cold virus that is used to deliver the spike protein of the coronavirus into the body, say Rolf Marschalek, a professor at Goethe university in Frankfurt, and colleagues. The mRNA vaccines developed by Pfizer/BioNTech and Moderna do not use this delivery system and there have been no blood clotting cases linked to them.

Continue reading...

AstraZeneca did ‘not even try’ to meet Covid vaccine contract, EU tells court

Posted on by

Commission demands €10 per dose for each day of delay as compensation

The European Commission has demanded an urgent court order requiring AstraZeneca to deliver millions more vaccines to the bloc or face a hefty fine, in a case that may reflect its anger more than its need for doses.

“AstraZeneca did not even try to respect the contract,” the EU’s lawyer, Rafaël Jafferali, told a court in Brussels on Wednesday, saying the EU wanted €10 per dose for each day of delay as compensation for the company’s alleged non-compliance.

Continue reading...

Moderna jab stops Covid transmission in people aged 12 to 18, trial finds

Posted on by

Moderna becomes second manufacturer to announce successful trial results in adolescents

Mass vaccination of children against Covid-19 moved a step closer as Moderna became the second manufacturer to announce successful trial results, showing its vaccine can stop transmission in people aged 12 to 18.

Pfizer/BioNTech’s vaccine has already been given emergency approval for adolescents aged 12 to 15 in the US by the regulator, the Food and Drug Administration (FDA), after its trials were said to show better efficacy even than in participants aged 16 to 25. It has begun a trial in young children, from six months to 11 years old.

Continue reading...

AstraZeneca chief hits back at ‘armchair generals’ after criticism

Posted on by

Pascal Soriot defends firm and says its booster jab has performed well against new Covid variants in trials

The chief executive of AstraZeneca has defended the company against “armchair generals” and said its vaccine has a future.

Pascal Soriot disclosed the UK had priority access to the jab in a deal with Oxford University in return for investment and that it was only slightly less effective against the India variant than the strain identified in Kent.

Continue reading...

Covid vaccines: India export delay deals blow to poorer countries

Posted on by

Efforts in Africa and elsewhere hit by decision not to export AstraZeneca jab until end of year

Vaccine programmes across Africa and much of the developing world will suffer big delays after the world’s biggest producer said it would not be exporting the Oxford/AstraZeneca vaccine until the end of the year.

“We continue to scale up manufacturing and prioritise India … We also hope to start delivering to Covax and other countries by the end of this year,” Adar Poonawalla, chief executive of the Serum Institute of India (SII), said in a statement on Tuesday.

Continue reading...

Nearly 40% of AstraZeneca investors reject boss’s bonus rise

Posted on by

Covid vaccine maker passes its remuneration policy but suffers sizeable rebellion

AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive, Pascal Soriot, bigger bonus awards for the second consecutive year.

Nearly 40% voted against the policy, which could hand him pay and perks of nearly £18m for 2021.

Continue reading...

India records almost 4,200 Covid deaths in a day

Posted on by

County reports more than 400,000 new infections but experts suspect figures are gross underestimate

Covid-19 deaths surged past 4,000 for the first time in India on Saturday in one of the world’s worst outbreaks.

India reported a national record of 4,187 new deaths on Saturday.

Continue reading...

EU wants to mass produce three ‘course-changing’ Covid drugs from October

Posted on by

Health commissioner says plan is to reduce hospitalisation and tackle long-term impact of Covid

Three Covid medicines with the potential to “change the course” of the pandemic will be authorised for mass production and use in the EU by October under a European Commission plan.

Stella Kyriakides, the commissioner for health, said such a move would reduce hospitalisation and tackle the long-term impact of Covid, with one in 10 people reporting symptoms 12 weeks after infection.

Continue reading...

US support for Covid vaccine patent waivers puts pressure on EU and UK

Posted on by

Analysis: Joe Biden’s support for idea is vital but it won’t happen without backing of other rich nations

It was a “seismic decision” by Joe Biden, the US president, say campaigners who have fought for the demolition of patent protection on vaccines and drugs for decades. The US administration has amazed supporters and critics alike by throwing its considerable weight behind the pleas of South Africa, India and about 100 developing countries at the World Trade Organization to overturn patents on Covid vaccines in the interests of getting more of them, more cheaply and faster, to huge populations in need.

Patents preserve the profits of the multinational companies that make drugs and vaccines. They make it illegal for up to 20 years for manufacturers of generic medicines to turn out cheap copycat versions. In this pandemic where, as the World Health Organization says, no one is safe until everyone is safe, there is a powerful moral case for ditching them.

Continue reading...

AstraZeneca CEO hits back at Covid vaccine supply criticism

Posted on by

Pascal Soriot says firm is doing its best to produce more and ‘should be proud of what we did in the world’

AstraZeneca’s chief executive, Pascal Soriot, has mounted a robust defence of the drugmaker’s Covid-19 vaccine efforts, and said the business should be proud of what it has done for the world and is doing its “very best” to produce more, as the company faces legal action from the EU over delivery shortfalls, and shipments to poorer countries have also been delayed.

The company generated $275m (£197m) in revenues from the Covid vaccine it developed with Oxford University in the first three months of the year and shipped 48m doses to 120 countries through the global vaccine-sharing initiative Covax, 80% of which went to low and middle-income countries. In total, it has supplied more than 300m vaccine doses to more than 165 countries so far this year.

Continue reading...

EU starts legal action against AstraZeneca over vaccine shortfalls

Posted on by

Firm says it will ‘strongly defend itself’ against claim it breached agreement to supply Covid jab

AstraZeneca said it would “strongly defend itself in court” and highlighted its supply of 50m Covid vaccine doses to European countries as Brussels launched legal action against the pharmaceutical company over delivery shortfalls.

The Anglo-Swedish firm said it regretted the decision by the European commission to start a legal case over alleged breaches of an advance purchase agreement.

Continue reading...

EU asks states to back legal action against AstraZeneca

Posted on by

Commission move causes concern about bringing case against key supplier of Covid vaccines

EU capitals have been asked by the European commission to back legal action against AstraZeneca by the end of the week over an alleged breach of its contractual obligations to supply member states with its Covid vaccine.

At a meeting with commission officials on Wednesday, diplomats from some member states raised concerns about the wisdom of the move, warning against rushing into a decision that might further undermine confidence in the vaccine.

Continue reading...